Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

Review proposal consultation

Stakeholder matrix (PDF 219 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): review decision - December 2014 information

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix A - GE decision paper - December 2014

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix A - GE decision paper - December 2014 (PDF 496 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): review proposal october 2014 information

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix a - provisional matrix of stakeholders

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix a - provisional matrix of stakeholders (PDF 100 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix b - proposal paper presented to the Institute's Guidance Executive

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix b - proposal paper presented to the Institute's Guidance Executive (PDF 365 KB)

TA258 Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): review update - April 2013 information

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): equality impact assessment - guidance development

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): final appraisal determination information

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): final appraisal determination document

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): final appraisal determination document (PDF 275 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 357 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): consultee and commentator comments on the ACD

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Roche

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Roche (PDF 157 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): British Thoracic Society

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): British Thoracic Society (PDF 9.8 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Royal College of Pathologists

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Royal College of Pathologists (PDF 52 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): NCRI/Royal College of Physicians/RCR/ACP/JCCO

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): NCRI/Royal College of Physicians/RCR/ACP/JCCO (PDF 259 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Department of Health

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Department of Health (PDF 4.9 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): NHS Derby City

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): NHS Derby City (PDF 46 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Commissioning Support Appraisals Service

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Commissioning Support Appraisals Service (PDF 348 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): AstraZeneca UK

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): AstraZeneca UK (PDF 170 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Lilly

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Lilly (PDF 9.4 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): comments on the ACD received from the public through the NICE website

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): comments on the ACD received from the public through the NICE website (PDF 44 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): additional evidence submitted by Roche

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): additional evidence submitted by Roche (PDF 125 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Evidence Review Group critique of additional evidence

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appraisal consultation

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appraisal consultation document information

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): evaluation report

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): pre-meeting briefing

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): pre-meeting briefing (PDF 611 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Evidence Review Group report

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Evidence Review Group report

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Evidence Review Group report (PDF 1.26 MB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Evidence Review Group report addendum

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Evidence Review Group report addendum (PDF 425 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Evidence Review Group report - factual accuracy check

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Evidence Review Group report - factual accuracy check (PDF 88 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Evidence Review Group report - erratum following factual check

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Evidence Review Group report - erratum following factual check (PDF 417 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Roche

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Roche (PDF 5.75 MB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): manufacturer PAS submission

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Department of Health letter confirming PAS can be considered

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Department of Health letter confirming PAS can be considered (PDF 44 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): manufacturer PAS submission from Roche

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): manufacturer PAS submission from Roche (PDF 447 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): clarification

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): NICE clarification letter

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): NICE clarification letter (PDF 62 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): manufacturer response to the NICE clarification letter

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): manufacturer response to the NICE clarification letter (PDF 464 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): patient group, professional group and NHS organisation submission statements

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Royal College of Pathologists

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Royal College of Pathologists (PDF 71 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): joint submission from NCRI/Royal College of Physicians/RCR/ACP/JCCO

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): joint submission from NCRI/Royal College of Physicians/RCR/ACP/JCCO (PDF 106 KB)

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Lind

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): final scope

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): final matrix

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): response to consultee and commentator comments on the draft scope 

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): response to consultee and commentator comments on the provisional matrix

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): scoping EIA form

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix B - draft scope for consultation (pre-referral) March 2011

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix C - provisional matrix (pre-referral) March 2011